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Background: Increasing numbers of patients are receiving haplo-identical stem cell transplantation (haplo-SCT) for
treatment of acute leukemia with reduced intensity (RIC) or myeloablative (MAC) conditioning regimens. The impact of
conditioning intensity in haplo-SCT is unknown.
Methods: We performed a retrospective registry-based study comparing outcomes after T-replete haplo-SCT for
patients with acute myeloid (AML) or lymphoid leukemia (ALL) after RIC (n = 271) and MAC (n = 425). Regimens were
classified as MAC or RIC based on published criteria.
Results: A combination of post-transplant cyclophosphamide (PT-Cy) with one calcineurin inhibitor and mycophenolate
mofetil (PT-Cy-based regimen) for graft-versus-host disease (GVHD) prophylaxis was used in 66 (25 %) patients in RIC and
125 (32 %) in MAC groups. Patients of RIC group were older and had been transplanted more recently and more
frequently for AML with active disease at transplant. Percentage of engraftment (90 vs. 92 %; p = 0.58) and day
100 grade II to IV acute GVHD (24 vs. 29 %, p = 0.23) were not different between RIC and MAC groups. Multivariable
analyses, run separately in AML and ALL, showed a trend toward higher relapse incidence with RIC in comparison to
MAC in AML (hazard ratio (HR) 1.34, p = 0.09), and no difference in both AML and ALL in terms of non-relapse mortality
(NRM) chronic GVHD and leukemia-free survival. There was no impact of conditioning regimen intensity in overall survival
(OS) in AML (HR = 0.97, p = 0.79) but a trend for worse OS with RIC in ALL (HR = 1.44, p = 0.10). The main factor impacting
outcomes was disease status at transplantation (HR ≥ 1.4, p ≤ 0.01). GVHD prophylaxis with PT-Cy-based regimen was
independently associated with reduced NRM (HR 0.63, p= 0.02) without impact on relapse incidence (HR 0.99, p = 0.94).
Conclusions: These data suggest that T-replete haplo-SCT with both RIC and MAC, in particular associated with PT-Cy,
are valid options in first line treatment of high risk AML or ALL.
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Haplo-identical hematopoietic stem cell transplantation
(haplo-SCT) is an attractive transplant procedure since
it provides a possibility of transplantation to almost all
patients needing an allogeneic SCT. Historical approaches
of haplo-SCT performed with unmanipulated bone marrow
stem cell grafts, standard myeloablative conditioning, and
graft-versus-host disease (GVHD) prophylaxis were associ-
ated with high risks of graft rejection and severe GVHD
due to uncontrolled bi-directional recipient and donor allo-
reactivity [1–4]. Although the development of T cell de-
pleted haplo-SCT has allowed to control the risk of severe
GVHD, the poor T cell immune reconstitution observed in
these patients is associated with a high incidence of life-
threatening infections [5–10]. In the last decade, several
strategies of T cell replete bone marrow (BM) or peripheral
blood (PB) haplo-SCT have been developed with both
reduced intensity (RIC) and fully intensive myeloablative
conditioning (MAC) regimens and variable GVHD prophy-
laxis strategies [11–26]. While some groups have used a
combination of anti-thymocyte globulin (ATG) with im-
munosuppressive agents with or without monoclonal anti-
bodies such as rituximab and basiluximab [11–16], others
have adopted the Baltimore’s strategy [17–26] of in vivo T
cell depletion by the administration of high doses of cyclo-
phosphamide (Cy) on days 3 and 4 post-SCT (PT-Cy).
These approaches have improved immune reconstitu-
tion and reduced non-relapse mortality (NRM) of
haplo-SCT [20, 27–29]. In single center experiences,
these new haplo-SCT platforms allow similar transplant
outcomes than allo-SCT performed with HLA-matched
donors [30–37]. However, the optimal conditioning
regimen for haplo-SCT in acute leukemia remains a
question of debate.
In HLA-matched related or unrelated allogeneic SCT
for acute leukemia, several studies have reported a dose-
dependent effect of the intensity of the conditioning
regimen on disease control [38–40]. In this context, the
reduced risk of relapse after MAC is counterbalanced by
higher NRM leading to similar overall survival in MAC
and RIC [41–48]. In T-replete haplo-SCT, low risks of acute
and chronic GVHD, resulting in <20 % NRM at 1 to 5 years
after RIC and MAC, have been reported [17–26]. Relapse
incidence, however, varies from 35 to 60 % at 1-year post-
transplant and remained the major event after haplo-SCT
performed with RIC and PT-Cy [17–19, 23, 26].
Although these differences could be related to disease
risk at transplant [24, 25, 49], these observations raise
the question of the role of the conditioning regimen in-
tensity on leukemic control and transplant outcomes
after T-replete haplo-SCT.
To address this question, we performed a large retro-
spective registry study to compare the transplant out-
comes of 696 patients receiving a haplo-SCT after RIC(n = 271) to those transplanted after MAC (n = 425) for
acute leukemia.
Results
Patient, disease, and transplant characteristics
Details of patients, disease, and transplant characteristics
are summarized in Table 1. Six hundred and ninety-six
patients with AL were included in the study. Two hundred
and seventy-one patients received RIC and 425 MAC regi-
men before haplo-SCT between 2001 and 2012. Patients of
the RIC group were older with median age of 53 years
(range, 18–76) in comparison to 38 years (range, 18–4) for
the MAC group (p < 0.0001). Only 45 % of the patients
were ≤50 years of age in the RIC group vs. 70 % in the
MAC group (p < 0.0001). The median follow-up of surviv-
ing patients in the RIC group was 15 (range, 1–73) months,
while that of the MAC group was 22 (range, 1–142)
months (p = 0.007). Significantly higher numbers of patients
were transplanted for acute myeloid (AML) in the RIC than
in the MAC group (80 vs. 67 %), while more lymphoid
leukemia (ALL) recipients were documented in the MAC
cohort (33 vs. 20 %; p < 0.0001). There were more patients
in CR1 in the MAC group (41 vs. 29 %) and with active
disease in RIC compared to MAC groups (47 vs. 31 %;
p < 0.0001). The other pre-transplant characteristics
were similar between RIC and MAC groups, and the
majority of patients were transplanted from 2008 to
2012 in both groups (91.5 % in RIC and 82.6 % in
MAC) (Table 1).
The indication for haplo-SCT was high risk disease in
the majority of patients in both groups, with 71 and
59 % of patients in RIC and MAC groups, respectively,
transplanted in advanced phase or active disease.
Details of transplant characteristics, conditioning, and
GVHD prophylaxis regimens are summarized in Table 2.
The majority of patients in the RIC group received PB
stem cells (65 %) compared to a similar distribution of
PB and BM as stem cell source in the MAC cohort (52.5
and 47.5 %, respectively; p = 0.001). The percentage of
patients receiving in vivo T cell depletion, mainly per-
formed with Thymoglobulin, was not significantly differ-
ent between the two groups (p = 0.26). Apart from
in vivo T cell depletion, GVHD prophylaxis consisted of
the combination of one calcineurin inhibitor with myco-
phenolate mofetyl (MMF) alone, or in association with
methotrexate (MTX) +/− Basiluximab (anti-CD25) or
post-transplant cyclophosphamide (PT-Cy). A calcine-
urin inhibitor +MMF and/or MTX +/− Basimuximab
was used in 31 and 54 % of the patients in the RIC and
MAC groups, respectively, while the association of a cal-
cineurin inhibitor +MMF with PT-Cy (PT-Cy + CsA/
Tacro +MMF) was applied in 25 and 32 % of patients of
the RIC and MAC groups, respectively. Another fre-
quent combination was sirolimus and MMF, used in
Table 1 Patient and disease characteristics
Patient characteristics RIC MAC p value
Number of patients 271 425
Recipient age at SCT (years, range) 53 (18–76) 38 (18–74) <10−4
Recipient age (by classes), n (%) <0.0001
< 30 46 (17.0 %) 148 (34.8 %)
30–40 32 (11.8 %) 82 (19.3 %)
40–50 45 (16.6 %) 98 (23.1 %)
≥ 50 148 (54.6 %) 97 (22.8 %)
Recipient gender, n (%) 0.42
Male 153 (56.5 %) 252 (59.6 %)
Female 118 (43.5 %) 171 (40.4 %)
Year of SCT (median), year (%) 2010 2011 0.65
2001–2007 23 (8.5 %) 74 (17.4 %) <0.0001
2008–2012 248 (91.5 %) 351 (82.6 %)
Interval from diagnosis to SCT (days, range) 299 (52–3892) 272 (41–3689) 0.24
Donor age 37 years (19–71) 42 years (12–70) 0.83
Donor age (by classes), year (%) 0.55
< 30 39 (29.3 %) 54 (29.2 %)
30–40 32 (24.1 %) 33 (17.8 %)
40–50 29 (21.8 %) 46 (24.9 %)
≥ 50 33 (24.8 %) 52 (28.1 %)
Donor gender, n (%) 0.69
Male 138 (50.9 %) 223 (52.5 %)
Female 133 (49.1 %) 202 (47.5 %)
Female donor to male recipient, n (%) 76 (28 %) 119 (28.1 %) 0.98
Diagnosis, n (%) <0.0001
AML 217 (80.1 %) 286 (67.3 %)
Good cytogenetics 8 (6 %) 19 (14 %)
Intermediate cytogenetics 47 (37 %) 53 (39 %)
Poor cytogenetics 19 (15 %) 18 (13 %)
Secondary AML 54 (42 %) 45 (33 %)
Missing cytogenetics 89 (41 %) 151 (53 %)
ALL 54 (19.9 %) 139 (32.7 %)
Phi+ ALL 15 (54 %) 27 (36 %)
Missing cytogenetics 26 (48 %) 64 (46 %)
Disease status at SCT, n (%) <0.0001
CR1 78 (28.8 %) 175 (41.2 %)
≥ CR2 67 (24.7 %) 118 (27.8 %)
Active disease 126 (46.5 %) 132 (31.1 %)
Karnosky at SCT, n (%) 0.05
≤ 80 % 101 (39.9 %) 109 (32 %)
> 80 % 152 (60.1 %) 232 (68 %)
Missing 18 (6.7 %) 84 (19.8 %)
Patient positive CMV serology, n (%) 213 (79.8 %) 311 (78.3 %) 0.66
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Table 1 Patient and disease characteristics (Continued)
CMV risk, n (%) 0.06
Low 35 (13.3 %) 59 (15.2 %)
Intermediate 169 (64.2 %) 272 (69.3 %)
High 59 (22.4 %) 56 (14.5 %)
AML acute myeloid leukemia, ALL acute lymphoid leukemia, CMV cytomegalovirus, CMV risk low = negative recipient and donor serology, high positive recipient
and negative donor serology, intermediate all other combinations, CR complete remission, SCT stem cell transplantation
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of conditioning and GVHD prophylaxis was dependent
on centers’ protocols and strategies of transplantation.
Donor lymphocyte infusion (DLI) was reported in 24
(8.9 %) in RIC and 36 (8.5 %) in MAC groups. Among
those, DLI was pre-emptive for 11 patients (4 % of
patients) in RIC and 14 (3 %) in MAC groups.
Engraftment and GVHD
Conditioning regimen specific engraftment and GVHD are
summarized in Table 3. Ninety percent of patients in theTable 2 Transplant characteristics
Transplant characteristics RIC MAC p value
Number of patients 271 425
Source of stem cells 0.001
BM 95 (35.1 %) 202 (47.5 %)
PB 176 (64.9 %) 223 (52.5 %)
Conditioning regimen
Chemotherapy-based 200 (73.8 %) 306 (72 %)
TBI-based 71 (26.2 %) 119 (28 %)
In vivo T depletion 0.26
Yes 140 (51.7 %) 201 (47.3 %)
Thymoglobulin 127 (91 %) 185 (92 %)
Lymphoglobulin 2 (1 %) 1 (0.5 %)
Alemtuzumab 11 (8 %) 15 (7.5 %)
No 131 (48.3 %) 224 (52.7 %)
Post-transplant GVHD prophylaxis <0.0001
CsA/FK506 +MMF or MTX 61 (23.2 %) 120 (30.3 %)
CsA +MMF +MTX 2 (0.8 %) 55 (13.9 %)
CsA +MMF +MTX + Basiliximab 19 (7.2 %) 40 (10.1 %)
PT-Cy + CsA/FK506 +MMF 66 (25.1 %) 125 (31.6 %)
Sirolimus + MMF 87 (33.1 %) 10 (2.5 %)
Other 28 (10.6 %) 46 (11.6 %)
DLI NS
No DLI 247 (91.1 %) 389 (92.5 %)
Pre-emptive DLI 11 (4.1 %) 14 (3.3 %)
DLI after relapse 13 (4.8 %) 22 (5.2 %)
BM bone marrow, Bu busulfan, CSA cyclosporine, Cy cyclophosphamide, DLI
donor lymphocyte injection, Flu fludarabine, MMF mycophenolate mofetyl, MTX
methotrexate, PB peripheral blood, PT-CY post-transplant cyclophosphamide, TBI
total body irradiationRIC group engrafted vs. 92 % in the MAC group (p = 0.58).
The median day for ANC> 500/μL was 17 (range, 3–75)
and 18 (range, 6–63) days in MAC and RIC groups,
respectively (p = 0.007). The incidences of day 100
grade II–IV (29 vs. 24 %; p = 0.23) and III–IV (10.7 vs.
10.9 %; p = 0.96) acute GVHD were not significantly
different between MAC and RIC groups, respectively.
As shown in Table 5, in multivariate analysis, the only
factor associated with increased grade II–IV acute
GVHD was the use of PB in comparison to BM stem
cells (hazard ratio (HR) 1.96; 95 % CI, 1.32–2.92; p =
0.0008). Two-year incidence of chronic GVHD was similar
between the different conditioning groups: 25 % (95 % CI,
19–31) in RIC vs. 32 % (95 % CI, 28–37) in MAC groups;
(p = 0.14). There was no difference of incidence of
cGVHD in AML and ALL groups (Table 4). In multivari-
ate analysis, chronic GVHD was not significantly different
between RIC and MAC groups (HR 0.80; 95 % CI, 0.56–
1.14; p = 0.21). The only factor associated with chronic
GVHD was the use of PB in comparison to BM stem cells
(HR 1.64; 95 % CI, 1.16–2.30; p = 0.005) (Table 5).
Toxicity and NRM
There was no difference in NRM at 2 years between RIC
and MAC groups in univariate (33 %; 95 % CI, 29–38;Table 3 Engraftment and GVHD
RIC MAC p value
Total number of patients 271 425
Engraftment 235 (90.4 %) 383 (91.7 %) 0.58
Non-engraftment 25 (9.8 %) 35 (8.4 %)
Missing 11 7
Acute GVHD
Grade 0–I, n (%) 202 (75.6 %) 293 (71.5 %) 0.23
Grade II–IV, n (%) 65 (24.4 %) 117 (28.5 %)
Grade III–IV, n (%) 29 (10.9 %) 45 (10.7 %) 0.96
Missing, n 4 15
Chronic GVHDa 24.7 % (19–30.9) 32.1 % (27.3–37.1) 0.14
Limited, n 29 76
Extensive, n 22 36
Missing, n 2 5
GVHD graft-versus-host disease
a2-year cumulative incidence
Table 4 Comparison of 2-year outcomes between MAC and RIC haplo-SCT according to disease status
Disease Patients group and p value RI NRM LFS OS cGVHD
Diagnosis AML 36.1 % (31.6–40.6) 31.6 % (27.4–35.9) 32.2 % (27.7–36.7) 37.7 % (33.1–42.4) 29.2 % (24.8–33.7)
ALL 40 % (32.5–47.3) 32.9 % (28.6–37.2) 27.2 % (20.2–34.1) 33.3 % (25.9–40.7) 29.8 % (22.8–37.2)
p 0.43 0.87 0.45 0.40 0.67
All patients
CR1 RIC 30.1 % (19.1–41.9) 31.1 % (24.1–38.3) 38.9 % (26.4–51.3) 46.9 % (34.1–59.8) 26 % (15–38.3)
MAC 21.5 % (15.4–28.3) 29.1 % (22.2–36.3) 49.1 % (41.2–57.1) 55.4 % (47.5–63.4) 41 % (32.8–48.9)
p 0.21 0.80 0.42 0.64 0.10
≥ CR2 RIC 38.5 % (25.8–51.1) 36.8 % (28.2–45.5) 24.6 % (13.1–36.1) 29.8 % (17.7–41.9) 29.6 % (17.5–42.8)
MAC 30 % (21.5–39) 27.8 % (19.7–36.4) 42.2 % (32.6–51.7) 47.7 % (38–57.5) 37 % (27.4–46.6)
p 0.38 0.25 0.06 0.07 0.53
Active dis. RIC 55.8 % (45.9–64.6) 32.9 % (24.5–41.5) 11.3 % (5–17.5) 14.3 % (7.3–21.3) 21.4 % (13.8–30.1)
MAC 51.9 % (42.3–60.6) 37.1 % (28.6–45.7) 11 % (4.7–17.2) 18.5 % (11.2–25.7) 15.2 % (9.2–22.7)
P 0.52 0.38 0.64 0.60 0.29
Active dis active disease, cGVHD chronic graft-versus-host disease, CR complete remission, LFS leukemia-free survival, NRM non-relapse mortality, MAC myeloabla-
tive conditioning, OS overall survival, RI relapse incidence, RIC reduced intensity conditioning
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and multivariate analyses (HR 0.95; 95 % CI, 0.69–1.31;
p = 0.76) (Table 5) in the total population of patients.
When analyzed separately, there was no difference
neither between AML and ALL in univariate analysis
(31.6 %; 95 % CI, 27–36; in AML vs. 33 %; 95 % CI,
28–37 in ALL; p = 0.87) (Table 4). In addition, in
multivariate analysis, the intensity of the conditioning
had no significant impact on NRM in AML and ALL
groups (Table 5).
Among all patients, in univariate analysis, there was no
difference in NRM at 2 years between the two groups for
patients transplanted in CR1 (Table 4 and Fig. 1), in ≥CR2
or with active disease (Table 4). In multivariate analysis,
however, active disease at transplant was associated with a
higher risk of NRM (HR 1.86; 95 % CI, 1.34–2.59; p =
0.0002), while the use of PT-Cy + CsA/Tacro +MMF was
associated with decreased NRM as compared to other
GVHD prophylaxis (HR 0.63; 95 % CI, 0.44–0.92; p =
0.02) (Table 5 and Fig. 3). There was no impact of recipi-
ent age at transplant, type of disease (ALL vs. AML),
source of stem cells (PB vs. BM), and year of transplant
(Table 5).
The main causes of NRM were infectious complica-
tions in 53 (32 %) vs. 75 (33 %) patients and GVHD in
23 (14 %) vs. 36 (16 %) of patients in RIC vs. MAC
groups, respectively. Death from organ toxicity was very
low in both groups. In particular, sinusoidal obstructive
syndrome (SOS) was reported in 2 (1.2 %) and 5 (2.2 %)
of patients in RIC and MAC groups, respectively.
Relapse
Overall RI at 2 years was comparable between AML and
ALL (36.1 % in AML and 40 % in ALL, p = 0.43) (Table 4).However, since disease status at transplant was signifi-
cantly different between the two conditioning groups
(Table 1), relapse incidence and survivals were analyzed
separately for all patients transplanted in CR1, ≥ CR2, and
with active disease (Table 4). Overall RI at 2 years for pa-
tients transplanted in CR1, ≥ CR2, and with active disease
were 23.9, 33.1, and 53.6 %, respectively. In univariate ana-
lysis, RI at 2 years was similar between RIC and MAC
groups for patients in CR1 (30 %; 95 % CI, 19–42 vs. 22 %;
95 % CI, 14–28 %; respectively; p = 0.21) (Table 4 and
Fig. 1), in ≥CR2 (39 %; 95 % CI, 26–51 vs. 30 %; 95 % CI,
22–39 %; respectively; p = 0.38) or with active disease
(56 %; 95 % CI, 47–65 vs. 52 %; 95 % CI, 42–61 %; respect-
ively; p = 0.52) (Table 4). In multivariate analysis, there
was a trend to a slight increase of RI in the RIC vs. MAC
group (HR 1.31; 95 % CI, 0.98–1.75; p = 0.07) (Table 5).
This trend was particularly observed in AML patients (HR
1.34; 95 % CI, 0.95–1.87; p = 0.09) (Table 5). In addition,
the risk of relapse was significantly higher for patients
transplanted in ≥CR2 (HR 1.46; 95 % CI, 1.01–2.13; p =
0.05) or with active disease (HR 4.43; 95 % CI, 3.20–6.12;
p < 0.0001) compared to CR1, and in ALL compared to
AML (HR 1.39; 95 % CI, 1.02–1.91; p = 0.04) (Table 5).
Despite reduced NRM, the RI was similar in patients hav-
ing received PT-Cy + CsA/Tacro +MMF in comparison to
other GVHD prophylaxis (HR 0.99; 95 % CI, 0.72–1.36; p
= 0.94) (Table 5 and Fig. 2).
Leukemia-free survival
LFS at 2 years was comparable between AML and ALL
(32.2 % in AML and 27.2 % in ALL, p = 0.67) (Table 4).
Overall LFS at 2 years for all patients transplanted in
CR1, ≥CR2, and with active disease were 46.3, 35.7, and
11.4 %, respectively. LFS at 2 years was similar between
Table 5 Multivariate analysis
Relapse NRM Acute GVHD Chronic GVHD LFS OS
p value HR (95 % CI) p value HR (95 % CI) p value OR (95 % CI) p value HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI)
RIC vs. MAC
All 0.07 1.31 (0.98–1.75) 0.76 0.95 (0.69–1.31) 0.32 0.82 (0.55–1.21) 0.21 0.80 (0.56–1.14) 0.27 1.13 (0.91–1.40) 0.44 1.09 (0.87–1.36)
AML 0.09 1.34 (0.95–1.87) 0.17 0.78 (0.54–1.12) 0.74 1.04 (0.81–1.34) 0.79 0.97 (0.75–1.25)
ALL 0.5 1.23 (0.67–2.26) 0.18 1.5 (0.83–2.72) 0.17 1.34 (0.88–2.05) 0.10 1.44 (0.94–2.22)
Age at SCT
1. <30 (ref) 1.00 1.00 1.00 1.00 1.00 1.00
2. (30–40) vs. 1 0.91 1.02 (0.68–1.54) 0.27 0.79 (0.51–1.20) 0.98 1.01 (0.60–1.70) 0.25 0.75 (0.46–1.22) 0.47 0.90 (0.67–1.20) 0.52 0.91 (0.67–1.23)
3. (40–50) vs. 2 0.43 0.84 (0.55–1.28) 0.74 1.08 (0.69–1.69) 0.98 1.01 (0.58–1.77) 0.70 0.91 (0.56–1.48) 0.74 0.95 (0.70–1.29) 0.79 0.96 (0.69–1.32)
4. ≥ 50 vs. 3 0.11 1.33 (0.93–1.90) 0.48 0.87 (0.59–1.28) 0.06 1.62 (0.98–2.70) 0.44 1.18 (0.77–1.79) 0.52 1.09 (0.84–1.42) 0.79 1.04 (0.79–1.36)
ALL vs. AML 0.04 1.39 (1.02–1.91) 0.37 1.16 (0.84–1.61) 0.65 1.10 (0.73–1.66) 0.50 1.13 (0.79–1.63) 0.03 1.28 (1.02–1.61) 0.03 1.30 (1.03–1.64)
Status at SCT
CR1 (ref) 1.00 1.00 1.00 1.00 1.00 1.00
≥ CR2 vs. CR1 0.05 1.46 (1.01–2.13) 0.45 1.15 (0.80–1.63) 0.35 1.24 (0.80–1.92) 0.23 1.25 (0.87–1.78) 0.05 1.30 (1.00–1.67) 0.01 1.40 (1.07–1.83)
Active dis. vs. CR1 <10–4 4.43 (3.20–6.12) 0.0002 1.86 (1.34–2.59) 0.85 1.04 (0.68–1.60) 0.45 1.17 (0.78–1.75) <10–4 2.94 (2.34–3.70) <10–4 2.92 (2.30–3.72)
PB vs. BM 0.85 1.03 (0.77–1.37) 0.59 1.09 (0.80–1.48) 0.0008 1.96 (1.32–2.92) 0.005 1.64 (1.16–2.30) 0.63 1.05 (0.85–1.30) 0.58 1.06 (0.85–1.32)
PT-Cy-based vs. other 0.94 0.99 (0.72–1.36) 0.02 0.63 (0.44–0.92) 0.11 0.69 (0.44–1.09) 0.46 1.15 (0.79–1.69) 0.10 0.82 (0.64–1.04) 0.16 0.83 (0.65–1.07)
Year of SCT
2001–2005 (ref) 1.00 1.00 1.00 1.00 1.00 1.00
2005–2007 0.86 1.08 (0.48–2.43) 0.74 0.89 (0.45–1.77) 0.62 1.24 (0.44–3.51) 0.17 2.03 (0.74–5.56) 0.89 0.96 (0.57–1.63) 0.84 1.06 (0.61–1.83)
2008–2012 0.98 0.99 (0.47–2.09) 0.22 0.68 (0.36–1.27) 0.27 1.68 (0.67–4.22) 0.14 2.04 (0.80–5.19) 0.40 0.81 (0.50–1.31) 0.60 0.87 (0.53–1.44)
Active dis active disease, BM bone marrow, PT-Cy-based post-transplant cyclophosphamide associated to one calcineurin inhibitor and mycophenolate mofetyl, CR complete remission, GVHD graft-versus-host-disease,
















Fig. 1 Probability of (1a) relapse incidence (RI); (1b) non-relapse mortality (NRM); (1c) leukemia-free survival; and (1d) overall survival (OS) after
MAC or RIC haplo-SCT for AL in CR1
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(39 %; 95 % CI, 26–51 vs. 49 %; 95 % CI, 41–57 %,
respectively, p = 0.42) (Table 4 and Fig. 1) or with active
disease (11 %; 95 % CI, 5–18 vs. 11 %; 95 % CI, 5–17 %,
respectively, p = 0.64) (Table 4). There was a trend to-
wards worse LFS in RIC vs. MAC groups for patients
transplanted in ≥CR2 (25 %; 95 % CI, 13–36 vs. 42 %;
95 % CI, 33–52 %; respectively; p = 0.06) (Table 4). How-
ever, in multivariate analysis, LFS was no different
between RIC and MAC groups for all patients (HR 1.13;
95 % CI, 0.91–1.40, p = 0.27), as well as for AML (HR
1.04; 95 % CI, 0.81–1.34, p = 0.74) and ALL (HR 1.34;Fig. 2 Probability of overall survival (OS) after MAC or RIC haplo-SCT for AL95 % CI, 0.88–2.05, p = 0.17) patients (Table 5). Multi-
variate analysis showed lower LFS in patients trans-
planted in ≥CR2 (HR 1.30; 95 % CI, 1.00–1.67; p = 0.05)
or with active disease (HR 2.94; 95 % CI, 2.34–3.70; p <
0.0001) compared to CR1, and in ALL compared to
AML (HR 1.28; 95 % CI, 1.02–1.61; p = 0.03) (Table 5).
Overall survival
Overall survival (OS) at 2 years was comparable
between AML and ALL (37.7 % in AML and 33.3 % in
ALL, p = 0.40) (Table 4). Overall OS at 2 years for pa-
tients transplanted in CR1, ≥CR2, and with activein (2a) ≥ CR2 and (2b) with active disease at transplant
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2 years was similar in RIC and MAC groups for pa-
tients transplanted in CR1 (47 %; 95 % CI, 34–60 vs.
55 %; 95 % CI, 48–63 %, respectively, p = 0.64) (Table 4
and Fig. 1) or with active disease (14 %; 95 % CI, 7–21
vs. 19 %; 95 % CI, 11–26 %, respectively, p = 0.60)
(Table 4 and Fig. 2). There was a trend towards worse
OS in RIC as compared to MAC groups for patients
transplanted in ≥CR2 (30 %; 95 % CI, 18–42 vs. 48 %;
95 % CI, 38–58 %; respectively; p = 0.07) (Table 4 and
Fig. 2). In multivariate analysis, OS was no different be-
tween RIC and MAC groups in the total cohort of pa-
tients (HR 1.09; 95 % CI, 0.87–1.36, p = 0.44) (Table 5)
and in AML patients (HR 0.97; 95 % CI, 0.75–1.25, p =
0.79). Although not significant, there was a trend for a
worse OS with RIC in ALL patients (HR 1.44; 95 % CI,
0.94–2.22, p = 0.10) (Table 5). Of note, 39 % of ALL
patients receiving a RIC had active disease at trans-
plantation in comparison to 24 % of those transplanted
with MAC (p = 0.03). Multivariate analysis also showed
lower OS in patients transplanted in ≥CR2 (HR 1.40;
95 % CI, 1.07–1.83; p = 0.01) or with active disease (HR
2.92; 95 % CI, 2.30–3.72; p < 0.0001) compared to CR1,
and in ALL compared to AML (HR 1.30; 95 % CI,
1.03–1.64; p = 0.03) (Table 5).
Discussion
The development of T-replete haplo-SCT for the treat-
ment of hematological malignancies has been consider-
able over the last 5 to 10 years. Several RIC and MAC
regimens have been designed by different groups at the
same time with GVHD prophylaxis regimens based
either on the Baltimore’s approach using PT-Cy [17–26]
or the combination of several immunosuppressive drugs
with in vivo T cell depletion with monoclonal antibodies
[11–16]. They all demonstrated the feasibility of such
transplants with limited NRM (≤20 % at 1 year) and
promising survival rates, in particular in patients trans-
planted in CR [24, 25, 49]. However, comparative studies
between the different transplant strategies had not been
performed. Our study represents the first large retrospect-
ive analysis comparing transplant outcomes between RIC
and MAC T-replete haplo-SCT for AML and ALL. In
AML, our results show similar LFS and OS in patients re-
ceiving RIC and MAC regimens after adjustment for dis-
ease risk at transplant. In ALL, there was a trend for
worse OS with RIC not related to increase relapse but ra-
ther a trend for increase NRM. This might be explained
by higher proportions of patients with advanced disease in
the RIC group.
In multivariate analysis, two factors impacted LFS and
OS: disease status at transplant in all patients and in the
AML and ALL subgroups (data not shown), and type of
leukemia. Patients transplanted for ALL or in ≥CR2 hadhigher risk of relapse, while those transplanted with ac-
tive disease had increased RI and NRM. Reduced anti-
leukemic effect of allo-SCT with higher relapse rates in
ALL in comparison to AML is well known in both non-
haplo and haplo-SCT settings [50, 51]. As reported by
other groups, outcome of RIC and MAC haplo-SCT in
patients transplanted with active disease are poor, with
relapse rates above 50 %, increased NRM, and OS below
20 % [13, 17–19, 22], confirming the need for developing
innovative transplant strategies for those patients. In this
series, patients transplanted in advanced disease phase
(CR2 and beyond) had a higher risk of relapse and lower
survival rates in comparison to those transplanted in
CR1. We also observed a trend in univariate analysis to-
wards reduced LFS and OS after RIC vs. MAC in this sub-
set of patients. These results are in contradiction with
those reported in smaller series of patients allo-grafted
with RIC or MAC haplo-SCT [13, 22]. However, in their
last reports, the Bacigalupo’s group also showed poorer
outcome of patients transplanted in ≥CR2 [24, 32]. Our
results confirm better transplant outcomes in patients
transplanted in CR1 with an OS of about 50 % at 2 years,
independently of the intensity of the conditioning and of
recipient age (data not shown). Altogether, these results
suggest that haplo-SCT should be considered in the first
line of treatment in high risk AML and ALL and can be
performed with MAC or RIC according to patient’s age
and co-morbidities.
Cumulative incidences of acute and chronic GVHD
were similar between RIC and MAC. Grade II–IV
acute GVHD occurred in 25 % of patients transplanted
with RIC and 29 % of those receiving a MAC, while
chronic GVHD was observed in 25 and 32 % of them,
respectively. These results are in line with the re-
ported incidences of GVHD after T-replete haplo-SCT
associated with different strategies of in vivo T cell
depletion [13–15, 17–26] and confirm the reduction
of GVHD rates with such strategies in a multicenter
experience. The use of PB vs. BM stem cells was asso-
ciated with increased risk of acute and chronic GVHD
but had no impact on the incidence of NRM and sur-
vivals. While the use of PB is also associated with
increased chronic GVHD in other HLA-matched trans-
plant settings [52, 53], its impact on the incidence of acute
GVHD is more debatable. In haplo-SCT with RIC and
PT-Cy, Castagna et al. could not find significant increase
of acute GVHD with PB in comparison to BM [54]. In this
study, the use of PB was associated with higher risk of
grade II–IV acute GVHD independently of the intensity of
the conditioning regimen and of the use of PT-Cy. Be-
cause of the heterogeneity of the conditioning and GVHD
prophylaxis regimens, we believe that the potential impact
of the stem cell source on the incidence of acute GVHD
in haplo-SCT needs further investigation.
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However, NRM was above 30 % in both groups, includ-
ing in patients transplanted in CR1, which is higher than
the levels below 20 % reported with T-replete haplo-SCT
independently of the type of GVHD prophylaxis in sin-
gle centers’ experiences [12, 13, 17–26]. Apart from dis-
ease status, the only factor impacting NRM in
multivariate analysis was the use of PT-Cy in association
to one calcineurin inhibitor and MMF in the prophylaxis
of GVHD. NRM with PT-Cy + CsA/Tacro +MMF was
closed to 20 % at 2 years (Fig. 3b), as described by the
Baltimore’s group [17–19]. Reduction of NRM with PT-
Cy was due to decreased mortality from GVHD (data
not shown) without significant reduction in the inci-
dence of acute and chronic GVHD, suggesting that PT-
Cy ameliorates the severity of GVHD. While there was a
trend for an increased incidence of relapse in RIC vs.
MAC in multivariate analysis adjusted for disease risk,
as observed in non-haplo-identical SCT [38–40], inter-
estingly, patients receiving PT-Cy + CsA/Tacro +MMF
did not have increased risk of relapse. Altogether, these
data suggest that the association of PT-Cy with one cal-
cineurin inhibitor and MMF represents a safer platform
for GVHD prophylaxis in haplo-SCT with reduced NRM
without impact on relapse incidence.
In comparison to the data reported by the Baltimore’s
group of haplo-SCT performed with a Fludarabine-Fig. 3 Probability of (3a) relapse incidence (RI); (3b) non-relapse mortality (NRM
Tacro +MMF as GVHD prophylaxisCyclophosphamide-low dose TBI RIC and PT-Cy, the
data of RIC with PT-Cy in this multicenter experience
confirm that this approach is associated with low risks
of GVHD and provides lower NRM. Although, PT-Cy is
not associated to an increased risk of relapse, its inci-
dence remains however the major post-transplant event
with 30 % incidence at 2 years in patients transplanted
in CR1 in our series. Thus, although this platform seems
safer, strategies for improvement are needed. In this ob-
jective, adaptation of conditioning intensity, the use of
PBSC together with post-transplant immunomodulation,
and preventive anti-leukemia targeted strategies might
improve the outcome.
Conclusions
We recognize that this study has several limitations.
First, it is retrospective and registry-based with imper-
fectly reported cytogenetics data, and the reasons for the
choice of the intensity of conditioning regimen and
GVHD prophylaxis were unknown but mainly dependent
on centers’ protocols and experience. Second, the condi-
tioning regimens and GVHD prophylaxis used were very
heterogeneous, and patient characteristics varied among
the groups for multiple factors including age, type of
leukemia, and disease status at transplantation. Despite
these limitations, the results described in this large retro-
spective study confirm single center experiences of the); (3c) LFS, and (3d) OS after haplo-SCT for AL with or without PT-Cy + CsA/
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RIC, in particular using PT-Cy as GVHD prophylaxis, in
first line treatment of high risk AML and ALL. Prospect-
ive comparative studies are required to determine the op-
timal conditioning and GVHD prophylaxis as well as the
place for post-transplant immunomodulation or targeted
therapeutic strategies.
Methods
Study design and data collection
This was a retrospective multicenter analysis. Data were
provided and approved for this study by the acute
leukemia working party (ALWP) of the EBMT group
registry. The latter is a voluntary working group of more
than 500 transplant centers that are required to report all
consecutive stem cell transplantations and follow-ups
once a year. Audits are routinely performed to determine
the accuracy of the data. The study protocol was approved
by the institutional review board at each site and complied
with country-specific regulatory requirements. The study
was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines. All
patients provided written informed consent authorizing
the use of their personal information for research pur-
poses. Eligibility criteria for this analysis included adult
patients (age >18 years) with AL, transplanted between
2001 and 2012, from an HLA-haplo-identical donor with
bone marrow (BM) or G-CSF mobilized peripheral blood
(PB) stem cells. All donors were HLA-mismatched at least
at two loci (≤8/10) (-A, -B, -C, DRB1, -DQB1). Exclusion
criteria were previous allogeneic or cord blood transplant-
ation and ex vivo T cell depleted stem cell graft. Variables
collected included recipient and donor characteristics
(age, gender, CMV serostatus), disease status at transplant,
transplant related-factors including conditioning regimen,
pre-transplant immunosuppression (in vivo T cell deple-
tion with anti-thymocyte globuline or alemtuzumab vs.
none), stem cells source (BM or PB), GVHD prophylaxis
(PT-Cy + CsA/Tacro +MMF vs. others), and outcome
variables (acute and chronic GVHD, relapse, NRM,
leukemia-free survival (LFS), OS, and causes of death).
Regimens were classified as MAC or RIC based on pub-
lished criteria [55]. Grading of acute and chronic GVHD
was performed using established criteria [56]. Chronic
GVHD was classified as limited or extensive according to
usual criteria [57]. The list of institutions reporting data
included in this study is provided in the supplemental data
(Additional file 1: Table S1).
Statistical analysis
The primary end point of the study was overall (OS) and
leukemia-free survival (LFS). Secondary endpoints included
disease relapse incidence (RI), non-relapse mortality
(NRM), engraftment, incidences, and severity of acute andchronic GVHD. LFS was defined as survival without re-
lapse or progression and NRM as death without relapse/
progression. The two groups according to the conditioning
regimen were compared by the chi-square method for
qualitative variables, whereas the Mann-Whitney test was
applied for continuous parameters. Univariate comparisons
were done using the log-rank test for OS, LFS, and Gray’s
test for RI, NRM, and GVHD cumulative incidences.
Multivariate analyses were performed using logistic regres-
sion for complete remission (CR) rate and Cox propor-
tional hazards model for all other endpoints. Factors
differing in terms of distribution between the two groups
and factors associated with a p value less than 0.15 by uni-
variate analysis were included in the final model. All tests
were two-sided. The type I error rate was fixed at 0.05 for
the determination of factors associated with time to event
outcomes. Statistical analyses were performed with SPSS
22.0 (IBM Corp., Armonk, NY, USA) and R 3.1.1 software
packages (R Development Core Team, Vienna, Austria).
Additional files
Additional file 1: Table S1. List of institutions reporting patients’ data
for the study. (DOCX 38 kb)
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